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OBJECTIVES: Submitting an HTA dossier a cardinal step in gaining market access
for new drugs. While funding decisions lay on an array of criteria a well designed
global value dossier (GVD) will facilitate development of national dossiers. In order
to gain a better understanding of the optimal structure of a GVD we reviewed
differences in requirements and recent changes in countries like Germany and
Spain. METHODS: Country-specific guidelines for HTA submissions and dossiers
submitted in the last 3 years have been scrutinized to identify the key differences
across European agencies (AWMSG, CVZ, DGFPS, G-BA, HAS/CEPS, NCPE, NICE,
SMC, TLV). Criteria reviewed included the guidelines strictness, and the need of
comparative effectiveness, health economic and budget impact evidence.
RESULTS: The majority of agencies reviewed (89%) have a well defined template
but the outline differs markedly between them. Differences relate to the requested
contents (clinical and budgetary outcomes only [33%] vs. a more cost-effectiveness
framework [67%]), and to the perspective from which the evidence is reviewed
(societal [17%] versus national health system or statuary health insurance perspec-
tive [83%]). Additional differences are the preferred type of economic model (cost
utility versus cost per clinical benefit) and budget impact (incremental budget im-
pact versus net costs) and weight given to indirect treatment comparisons when
head-to-head studies are lacking. CONCLUSIONS:Our review illustrates the lack of
standardization of the requirements across European HTAs. This renders the de-
velopment of a GVD easily adaptable to country-specific submissions, a difficult
task. Our review suggests that the GVD should be orchestrated around the needs
for NICE and implemented with the particularities of the different HTAs.
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OBJECTIVES:To provide early assessment of the process for reimbursement of new
drugs by the German Federal Joint Commission (GBA), which assesses “additional
clinical benefit” (ACB) for the new drug compared to an appropriate comparator.
METHODS: A database was created including the decisions by product and indica-
tion. A qualitative and descriptive statistical analysis was performed to examine
the relationship of ACB decisions to comparators, population size and complete-
ness of the submission. RESULTS: The database included data for 20 final resolu-
tions assessing ACB. Different descriptors of ACB have been used by the GBA in the
published resolutions including: “no additional benefit”; “small clinical benefit”;
“indication of additional clinical benefit, not quantifiable”; or “considerable clinical
benefit”. In 8 (40%) of the final resolutions, ACB was not proven, in 5 (25%) submis-
sions ACB was proven for the indicated population, and in 7 (35%) ACB was proven
only in a subset of the indicated population. For 3 of the 5 submissions where ACB
was proven for the indicated population, the resolution was based on the fact that
this was an orphan drug. Lack of data on an appropriate comparator was given as
the reason for the not proven decision for 4 submissions. The dossier was consid-
ered incomplete for 2 submissions. For three drugs, one for hypertension, one for
hypercholesterolemia and one for postoperative ocular inflammation following
cataract extraction, no dossiers were submitted and the products were allocated to
the appropriate reference price group. CONCLUSIONS: With the exception of res-
olutions for orphan drugs, all but two of the early ACB decisions have found proof
of benefit in only a subgroup of the indicated population. Lack of data on an appro-
priate comparator and target patient population was a common reason for a neg-
ative resolution.
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OBJECTIVES: Health economics and outcomes research (HE&OR) have become in-
creasingly important for Dutch policy makers to decide on the content of the stat-
utory insurance package. Pharmaceutical companies have been well developed in
conducting outcomes research and presenting health economics data in order to
access the insurance package, and reimbursement for their products. However,
HE&OR data are not the only objectives for successful reimbursement strategies.
The objective of this study was to analyse reimbursement trajectories in order to
unravel factors for successful market access. METHODS: A qualitative, retrospec-
tive study have been performed from 2008-2011. Period of study: 1999 -2010. In this
study market access trajectories of the three main TNF -blockers, and several
smaller trajectories of pharmaceutical and medical devices companies have been
analysed. Governmental and company documents and value dossiers were studied
and interviews (n19) were held with decision makers of the Ministry, the Health
Insurance Board, physicians, patient organizations, and responsible persons from
the companies. Because the financial reimbursement scheme in the Netherlands
has been changed by January 1st2012, the results are reanalysed and latest results
are added. RESULTS: Within the Dutch health care system, based on a neo-corpo-
ratist structure, many parties are involved in decision making processes. Pharma-
ceutical companies, scientific associations of physicians, and well-developed pa-
tient organizations are being invited to consultations with policy makers and the
Ministry. Our analysis shows that in depth knowledge of Dutch financing scheme
needs to be accompanied with mutual trust and converging goals of the several
parties. Those goals can easiest be converged on patients’ level. CONCLUSIONS:
Although Dutch policy makers are emphasising HE&OR for accessing the insurance
package, our study shows that important arguments for successful market access
are institutional trust and converging goals of the several parties and, from January
1, 2012, in-depth knowledge of the Dutch dedicated DRG-system.
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OBJECTIVES: Orphan drugs are subject to regulatory and reimbursement regula-
tions that differ with respect to application process and necessary documentation.
An orphan drug status granted by the European Commission gives marketing ex-
clusivity in the EU for 10 years after approval. Reimbursement hurdles are also
supposedly lower for orphan drugs in Europe than usually. METHODS: Definition
and assessment process of orphan drugs for reimbursement were reviewed and
analyzed. Differences to other drugs are outlined and reimbursement decisions
presented. RESULTS: The German law on health care reform (AMNOG) imple-
mented in 2011 requires that with market access newly approved products dem-
onstrate their innovation through a reimbursement dossier to avoid reference
group pricing. For orphan drugs, manufacturers must also submit a dossier but the
additional medical benefit is regarded as having been proofed by the market au-
thorization itself. Thus proof of additional benefit does not need to be presented
but information on relevant patient groups and on the extent of this additional
benefit. However, if annual sales of an orphan drug within the statutory health
insurance exceed 50 million EUR, a full assessment is made. For pirfenidone, the
first orphan drug assessed under the new law, IQWiG (Institute for Quality and
Efficiency in Health Care) declined an additional therapeutic benefit but the G-BA
(Joint Federal Committee) did not follow this conclusion in accordance to the law.
In Italy pirfenidone was grouped into the lowest reimbursement class. Unlike Ger-
many, Italy has special funds set aside for orphan drugs, France has an early access
program, and many countries are struggling with how to create a reimbursement
process that reflects the different regulatory provisions for orphans.
CONCLUSIONS: Although orphan drugs are often regarded as unquestioned reim-
burseable, differences in respective processes and assessments exists. Manufac-
turers are requested to build Market Access arguments carefully and expect chal-
lenges in orphan drug indications as well.
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OBJECTIVES: In 2011, Germany’s new health care reform (AMNOG) came into effect
requiring that with market access newly approved products demonstrate their
innovation to avoid reference group pricing. The manufacturer has to submit a
dossier proving additional benefit versus the appropriate comparator recom-
mended by the G-BA (Joint Federal Committee). On request of the G-BA, IQWiG
(Institute for Quality and Efficiency in Health Care) reviews the dossier and per-
forms the benefit assessment. Manufacturers, associations and experts can submit
comments and attend a hearing; thereafter the G-BA publishes its final resolution.
METHODS: Benefit assessments and G-BA decisions to date were reviewed and
analyzed case by case. Differences between IQWiG and G-BA evaluations are out-
lined and consequences depicted. RESULTS: Up to now 32 dossiers have been
submitted, 19 completed the whole process and further 8 will be finally assessed
shortly. About half of the products additional therapeutic benefit was granted al-
lowing price negotiations with the statutory health insurance. Not in all cases did
the G-BA follow IQWiG’s conclusions as for Eribulin and Pirfenidone (an Orphan
drug). The selection of the appropriate comparator treatment was the most con-
troversial issue between G-BA and pharmaceutical companies, followed by ques-
tions about evidence for and interpretation of benefit. Thus for Linagliptin no ad-
ditional benefit against the appropriate comparator is proven according to the G-BA
and the manufacturer challenges the process. Other critical methodology issues
included the definition of patient-relevant endpoints, use of surrogate endpoints,
determination of target patient populations and use of subpopulations.
CONCLUSIONS: Although in its second year, AMNOG is still a learning process for
all parties involved. Before initiating a dossier it is crucial to investigate possible
pitfalls around dossier development. New questions will emerge when it comes to
the assessment of drugs already on the market as it is now planned for DPP-4
inhibitors.
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OBJECTIVES: Exploring the use of population-level epidemiological data (i) within
the reimbursement decision making process, (ii) identifying recommendations and
requirements on that data, and (iii) investigating the role of that data for reim-
bursement decisions as stated in pharmacoeconomic guidelines. METHODS: We
piloted a comparative review of all national pharmacoeconomic guidelines pub-
lished in English (N26 out of 33) available through the ISPOR Website
http://www.ispor.org/PEguidelines/index.asp. RESULTS: The use of population-
level epidemiological data was addressed by 20 guidelines.16 mentioned the use
for economic evaluations, 4 (additionally) for budget impact analyses, and 4 (also)
for broader technology assessments. 14 guidelines provided explicit recommenda-
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tions on epidemiological data; 12 specified that the uncertainty surrounding epi-
demiological data should be addressed, especially in terms of the transferability of
international data. The party responsible for the conduct of the analysis (therefore
responsible for providing the epidemiological data) was named by 20 guidelines, of
which 14 explicitly referred to the marketing authorization holder. Furthermore,
an acceptable level of evidence was mentioned only by 4 guidelines (Australia,
Austria, Poland, and Scotland) and included surveys, registers, databases and ex-
perts’ opinions. The relevance of epidemiological data for final reimbursement
decisions was explicitly mentioned by 5 guidelines (Australia, Israel, Russia, Scot-
land, and South Africa). However, consequences for unacceptable epidemiological
evidence (i.e., cases not following recommendations or requirements) were only
indicated by Russia and Scotland in the form of refraining from giving positive
reimbursement advice. CONCLUSIONS: Population-level epidemiological data is
mentioned in 77% of the guidelines, but those focus mostly on issues of data trans-
ferability. Only few countries (19%) address the role of population-level epidemio-
logical data for reimbursement decisions. To reduce decision uncertainty, ap-
proaches to address the often occurring paucity of epidemiological evidence
should preferably be part of all pharmacoeconomic guidelines.
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OBJECTIVES: We investigated commonalities and significant differences in HTA
evidence requirements in the EU5 (Germany, France, UK, Italy and France) and the
implications on phase III programmes, focusing on three key, rapidly evolving
elements of HTA: choice of the comparator, Health-Related Quality of Life (HRQL)
and effectiveness. METHODS: In-depth, semi-structured 60-min telephone inter-
views were undertaken with 34 HTA experts across the EU5 (17 from HTA bodies
and Academia, 17 from pharma). RESULTS: An active comparator in phase III is
mandated or clearly preferred in all EU5 countries for HTA/payer purposes. It tends
to be the therapy most commonly used in clinical practice, although best practice
or cheapest therapy may be selected. Countries vary in the degree of flexibility in
the approach to comparative evidence. UK appears to be the most flexible in the
choice of comparator and acceptance of indirect evidence. Germany is the most
demanding (e.g. head-to-head data vs. multiple, specific comparators for multiple
sub-populations). HRQL is increasingly important in HTA, yet all respondents
agreed that, in practice, HRQL is still only supportive to ‘hard’ end-points such as
morbidity and mortality. Challenges in capturing HRQL as a measure of clinical
benefit and/or a way to derive utilities, were discussed. Demonstrating effective-
ness is becoming increasingly relevant to HTA, although efficacy data from phase
III trials still have the major role – the greatest challenge is the generalisation of
results to the wider, real-world patient population. Countries differ in their flexi-
bility to addressing the demonstration of effectiveness. CONCLUSIONS: Increased,
and sometimes contradictory, HTA-driven demands for evidence place strain on
phase III trials. Hopefully, as Germany, the UK and France .adapt their processes,
and Spain and Italy develop fuller capability, harmonisation of core HTA require-
ments will enable pharma to design more efficient evidence programmes. Sugges-
tions derived from this research will be presented.
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OBJECTIVES: It is often considered that the UK grants access to new medicines
upon marketing authorisation (MA) approval, while patients in countries such as
France or Belgium gain access only after significant delays. The objective is to
quantify differences in time to market access between the UK (excluding Scotland),
France and Belgium and to identify contributing factors. METHODS: We reviewed
submission and approval dates for all new chemical or biological entities that were
granted a MA by the European Commission (EC) between August 2006 and July
2011. Generics, fixed dose combinations, new formulations, and vaccines were
excluded. Information was collected from official health authority sources (i.e.
regulatory, health technology assessment, and pricing agencies; official journals;
national formularies). Results are presented as median days pre- and post-market-
ing authorisation (MA was defined as day 0). RESULTS: For the 111 drugs we iden-
tified, EC approval was granted a median of 428 days after submission of the ap-
plication and 64 days after the Committee for Medicinal Products for Human Use
issued a positive opinion. A first analysis suggested more drugs were marketed in
England (n97), than in France (n74) or Belgium (n62). NICE guidance, however,
was only issued for 29 products (21 positive opinions) after a median of 399 days
following MA. In France and Belgium, ministerial reimbursement decisions were
published in the Official Journal after 279 and 348 days, respectively. The time
needed for Belgian companies to submit a reimbursement dossier was variable
(median: 68 days; IQR: 21-235 days after MA). CONCLUSIONS: As product uptake is
negligible until NICE issues a positive guidance, English patients have access to
only a limited number of innovative drugs. French authorities appear to grant
access to more products and have shorter review timelines than their Belgian and
English counterparts. Dossier submission timelines may contribute to delays in
Belgium.
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OBJECTIVES: Describe and analyze the impact of the recognition of the Economic
and Public Health Assessment Committee (CEESP) as an official committee, part of
the French National Authority for Health (HAS), within the new code of social
security for drug market access. METHODS: We browsed website of French gov-
ernment, reviewed grey literature relating to the introduction of health economic
criteria in the recommendations of the CEESP and interviewed decison makers.
RESULTS: The remit of CEESP is to determine efficient strategies and edit recom-
mendations to support price negotiations. Products eligible for economic assess-
ment will be selected based on criteria to be defined and some areas of uncertainty
remain to be addressed. (1) Criteria for product selection: all products that state
innovative improvement, product with sales above €10 million per year, new mode
of action and products with potential extension of target population are likely to be
assessed; orphan designated product are not. At time of approval, the scope of
assessment will be relatively narrow and outstanding questions addressed during
reassessments 3 to 5 years later. (2) How the Transparency Committee (TC) and
CEESP will resolve divergent opinions: While TC only focus on clinical trials, CEESP
is expected to have a broader perspective. As both committees operate indepen-
dently, it is urgent that a clear process is established to clarify the resolution of
divergent opinion. (3) Methodology used for economic assessment: HAS published
guidelines for economic analysis. They remain very flexible even if some specific
recommendations were made (e.g. no cost benefit analysis, loss of productivity not
included in reference case, deterministic and probabilistic sensitivity analysis re-
quired). Finally no information is available to inform how CEEPS opinion will im-
pact pricing negotiation. CONCLUSIONS: Although application decrees are still to
be issued, there are important areas of uncertainty surrounding introduction of
health economics in market access of drugs in France.
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OBJECTIVES: Compared to small molecule generics, biosimilars have different
price drivers due to greater manufacturing complexity and stronger regulatory
hurdles. We looked to investigate historic trends in biosimilars pricing and assess
what may change in the future. In addition, we aimed to understand how the
recent FDA guidelines will shape pricing of biosimilars in the US. METHODS: In
order to understand the historic trends shaping biosimilars pricing, we conducted
secondary research into the pricing of 14 biosimilars in EU5 markets. Focusing on
qualitative analysis, we assessed three potential factors that shape current pricing:
1) Launch date; 2) Number of biosimilars available; and 30 Therapy area. Primary
research was conducted by surveying a selection of payers in order to understand
the current price drivers and how these will potentially change in the future. We
also assessed their expectations on how FDA pathway regulations will affect pric-
ing in the US. RESULTS: Historical analysis of biosimilar pricing indicated similar
pricing across the sample, with average pricing at a 20-30% discount relative to the
originator. These results indicated no significant correlation between the number
of biosimilars available, launch date or therapy area, suggesting that common
drivers such as development and manufacturing costs shape pricing across ther-
apy areas. Payers noted that future manufacturing costs (particularly for monoclo-
nal antibodies), regulatory hurdles, and phase IV trial requirements will maintain
upward pressure on biosimilar prices, but increasing competition over time would
likely bring down prices relative to originators. CONCLUSIONS: Historically, bio-
similar pricing has been driven by the date of launch and therapy area, in addition
to the high R&D costs of manufacturing. Predictions for the future indicate that
biosimilars pricing will maintain current levels due to competing pressures. Payers
in the US foresaw similar pricing trends, but did not expect as great a level of
discounting seen in the EU.
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OBJECTIVES: The social security system in Greece was characterized complex and
fragmented and unlike other countries, the existence of many insurance agencies
did not create any competition in the health system. In March 2011, the National
Organization for the Provision of Health Care (EOPYY) was established. The aim of
the study was to highlight stakeholder’s insights on the establishment of EOPYY
and their perceptions for the applicability of the reform. METHODS: A qualitative
study, using the method of semi-structured interviews was conducted using an
open-ended questions guide. In order to identify stakeholders at the very top of the
‘power’ list (decision makers) as well as people and groups whose opinion matters
in shaping reform policies (opinion leaders), we undertook a stakeholder mapping
and 24 targeted stakeholders were found. In total 17 interviews were conducted,
tape recorded, transcribed and content analyzed. RESULTS:According to the inter-
viewees, the setting-up of EOPYY was considered necessary and valuable, taking
into consideration that it will contribute to the consolidation of the benefits and the
enhancement of the Welfare State, the establishment of a modern system of pri-
mary health care and the enhancement of its negotiation power. Regarding the so
far implementation of the reform, stakeholders have reservations and are skeptical
about the specific goals and the orientation of the Organization. Notably, concerns
were focused on the reimbursement method of the doctors, on the selection crite-
ria and on the lack of a specific mission. CONCLUSIONS: Although, the stated
objectives of the implementation of EOPYY appear positive and ambitious, the
A312 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
